icon
0%

Elevance Health ELV - News Analyzed: 4,181 - Last Week: 99 - Last Month: 399

⇑ Analysis of Key Developments and Market Sentiments for Elevance Health ELV

Analysis of Key Developments and Market Sentiments for Elevance Health ELV
Oppenheimer & Co. Inc. and Vulcan Value Partners LLC have decreased their position in Elevance Health, although other brokerages maintain a "Buy" rating. The company's stock has recently increased 6.1% and outperformed competitors. Elevance's promising returns on capital are growing positively and the company reportedly has the capacity to take on additional debt. Northern Trust Corp and Prudential PLC have sold their Elevance Health shares. More positive outcomes include EVIDENCE Health's earnings exceeding Q1 estimates and its beneficial growth from continued increases in healthcare expenditure. Elevance Health also announced its presence at the Goldman Sachs Global Healthcare Conference. After partnering with CD&R, Elevance Health continues to focus on its Provider Services Arm, and Bank of America increased Elevance Health's price target to $646. Elevance Health has displayed strong behavior in healthcare business with substantial state contracts. Results for the first quarter of 2024 were announced, although the reactions were mixed with some concerns related to the premium price. The company is also set to pay a $1.63 dividend. Elevance Health has had new investments and was upgraded to "Buy". The company's provider arm is considered a near-term growth driver and its shares sold are being monitored. Recent reports suggest that the selling of Kroger's specialty pharmacy business to Elevance Health's CarelonRx could be beneficial.

Elevance Health ELV News Analytics from Tue, 19 Dec 2023 08:00:00 GMT to Sun, 09 Jun 2024 13:37:57 GMT - Rating 8 - Innovation 4 - Information 6 - Rumor 5

The email address you have entered is invalid.